tmem175 Antibody

What is TMEM175 and why is it significant in cellular biology?

TMEM175 (transmembrane protein 175) serves as an endosomal/lysosomal proton channel that catalyzes proton efflux from endosomes and lysosomes to maintain steady-state pH. It becomes activated at low pH (under 4.6) by luminal side protons, selectively mediating lysosomal proton release that balances V-ATPase activity for pH homeostasis. Additionally, it functions as a potassium channel at higher pH values, regulating potassium conductance in endosomes and lysosomes. This dual functionality is critical for lysosomal function, including autophagosome-lysosome fusion processes that are essential for cellular waste management and protein homeostasis .

How does TMEM175 structure relate to its function?

TMEM175 is a 55.6 kilodalton transmembrane protein with multiple transmembrane domains that form the pore structures necessary for its ion channel functions. The protein contains critical regions such as the fourth luminal loop (residues 278-291 in mouse TMEM175), which can be targeted by antibodies for experimental analysis. TMEM175 constitutes the pore-forming subunit of the lysoK(GF) complex that includes AKT proteins (AKT1, AKT2, or AKT3). Within this complex, TMEM175's channel is regulated through conformational changes induced by AKT, highlighting how structural elements directly influence channel gating and ion selectivity .

What are the key differences between TMEM175 across species?

TMEM175 orthologs have been identified in multiple species including humans, canine, porcine, monkey, mouse, and rat models. While the core functions of pH regulation and ion conductance are conserved, sequence variations exist that necessitate species-specific antibody targeting. For example, mouse TMEM175 antibodies often target the peptide sequence CEDNVPDPKDVQEK (residues 278-291), requiring consideration when designing cross-species experiments. These differences in protein sequence may impact how antibodies recognize the target, potentially affecting experimental outcomes when working with different model systems .

What criteria should researchers use when selecting a TMEM175 antibody?

Researchers should consider multiple factors when selecting a TMEM175 antibody: (1) Target epitope location - antibodies targeting different domains may yield different results depending on protein conformation and accessibility; (2) Validation evidence - prioritize antibodies with knockout validation data and multiple application validations; (3) Clonality - monoclonal antibodies generally offer higher specificity while polyclonal antibodies might provide stronger signals; (4) Species reactivity - ensure cross-reactivity with your experimental model; (5) Application compatibility - confirm suitability for intended applications (WB, IHC, ICC, etc.). The antibody should be validated specifically for TMEM175 detection, as demonstrated by appropriate controls including blocking peptides that can confirm specificity .

How can researchers validate the specificity of TMEM175 antibodies?

Proper validation requires a multi-pronged approach: (1) Western blot analysis comparing control samples with TMEM175 knockout or knockdown samples to confirm specificity; (2) Peptide competition assays using blocking peptides (such as BLP-PC175) to demonstrate signal reduction or elimination; (3) Immunohistochemical analysis in tissues with known TMEM175 expression patterns, with parallel negative controls; (4) Cross-validation using multiple antibodies targeting different epitopes to confirm consistent localization patterns. For example, TMEM175 antibodies should show specific immunoreactivity in brain regions such as the medial septum and piriform cortex, and this signal should be suppressible with the corresponding blocking peptide .

What are the most effective applications for TMEM175 antibodies in research?

TMEM175 antibodies have demonstrated effectiveness across multiple applications: (1) Western blotting (WB) - for protein expression level quantification in cell lysates and tissue homogenates; (2) Immunohistochemistry (IHC) - particularly useful for visualizing expression patterns in neuronal tissues; (3) Immunocytochemistry (ICC) and Immunofluorescence (IF) - for subcellular localization studies, especially in endosomal/lysosomal compartments; (4) ELISA - particularly using sandwich ELISA approaches with matched antibody pairs for quantitative protein detection; (5) Flow cytometry - for analyzing TMEM175 expression in specific cell populations. Each application requires specific optimization, including determining appropriate antibody dilutions (typically 1:200-1:300 for WB and IHC applications) .

What are the optimal protein extraction methods for TMEM175 detection by Western blot?

Effective TMEM175 detection requires careful consideration of its transmembrane nature: (1) Membrane protein extraction protocols using detergents like CHAPS, NP-40, or Triton X-100 are essential for complete solubilization; (2) Sample preparation should include protease inhibitors to prevent degradation; (3) Avoid excessive heating (>70°C) which may cause protein aggregation of transmembrane proteins; (4) Reducing agents should be included to break disulfide bonds; (5) Protein separation is optimally performed on 10-12% SDS-PAGE gels to accommodate the 55.6 kDa mass of TMEM175. Transfer conditions should be optimized for membrane proteins, potentially using lower methanol concentrations in transfer buffer. Western blot analysis has been successfully performed on various samples including rat spleen membranes, mouse spleen lysates, and human cell lines (SH-SY5Y, THP-1, and LNCaP) .

How should researchers optimize immunohistochemical staining for TMEM175?

For optimal TMEM175 immunohistochemical detection: (1) Tissue fixation methods significantly impact results - perfusion-fixed frozen brain sections have shown good results with anti-TMEM175 antibodies; (2) Antigen retrieval techniques may be necessary, particularly for formalin-fixed paraffin-embedded tissues; (3) Antibody dilutions around 1:300 have been effective for immunofluorescence detection; (4) Secondary antibody selection should match the host species of the primary antibody (e.g., goat anti-rabbit-AlexaFluor-488); (5) Include appropriate controls - negative controls omitting primary antibody and specificity controls using blocking peptides are essential. TMEM175 immunoreactivity has been successfully observed in neuronal populations within the medial septum and piriform cortex, appearing as punctate staining patterns consistent with endosomal/lysosomal localization .

What approaches are recommended for studying TMEM175 in cellular pH regulation experiments?

To study TMEM175's role in pH regulation: (1) Lysosomal pH measurements using ratiometric dyes (LysoSensor) or pH-sensitive fluorescent proteins targeted to lysosomes; (2) Patch-clamp electrophysiology of isolated lysosomes to directly measure proton conductance under different pH conditions; (3) Live-cell imaging with dual-labeled markers for lysosomes and pH indicators to observe dynamic pH changes; (4) Comparative studies between wild-type and TMEM175-deficient cells to evaluate the specific contribution to pH homeostasis; (5) Pharmacological manipulations using V-ATPase inhibitors (bafilomycin A1) to isolate TMEM175-dependent proton flux. These approaches should be conducted under carefully controlled pH conditions, particularly studying activation under acidic conditions (pH <4.6) where TMEM175 functions as a proton channel .

How does TMEM175 interact with AKT proteins in the lysoK(GF) complex?

TMEM175 forms a functional complex with AKT proteins (AKT1, AKT2, or AKT3) called the lysoK(GF) complex, which is activated by extracellular growth factors. The interaction dynamics involve: (1) AKT-mediated conformational changes in TMEM175 that regulate channel opening; (2) Growth factor signaling pathways that converge on this complex to modulate lysosomal function; (3) Potential phosphorylation events that may regulate interaction affinity or channel activity. To study these interactions, researchers should consider co-immunoprecipitation experiments with dual antibody detection, proximity ligation assays to visualize protein-protein interactions in situ, and functional assays measuring channel activity in response to growth factor stimulation. This complex is particularly significant as it represents a mechanism by which external growth signals can rapidly modulate lysosomal function .

What methodologies are most effective for investigating TMEM175's dual role as both proton and potassium channel?

Investigating TMEM175's dual ion channel functions requires sophisticated approaches: (1) Electrophysiological recordings under varying pH conditions to distinguish between proton and potassium conductance; (2) Ion substitution experiments to differentiate between K+ and H+ currents; (3) Site-directed mutagenesis of pore-forming regions to identify residues critical for ion selectivity; (4) Fluorescence-based ion flux assays using specific potassium or pH indicators; (5) Computational modeling of channel structures to predict ion permeation pathways. The transition between potassium channel mode (at higher pH) and proton channel mode (at lower pH, under 4.6) represents a fascinating aspect of TMEM175 biology that requires careful experimental design to elucidate the molecular mechanisms underlying this functional switch .

How can researchers effectively study TMEM175's role in autophagosome-lysosome fusion?

To investigate TMEM175's contribution to autophagosome-lysosome fusion: (1) Live-cell imaging with fluorescently tagged LC3 (for autophagosomes) and LAMP1 (for lysosomes) in wild-type versus TMEM175-depleted cells; (2) Electron microscopy to visualize fusion intermediate structures at ultrastructural resolution; (3) Biochemical fractionation to isolate and characterize autophagosomes and autolysosomes; (4) Autophagic flux assays measuring degradation of long-lived proteins or specific autophagic substrates; (5) Rescue experiments reintroducing wild-type or mutant TMEM175 into knockout cells to identify critical functional domains. Since TMEM175 regulates luminal pH stability, which is required for autophagosome-lysosome fusion, these approaches can help elucidate the mechanistic link between ion channel function and membrane fusion events during autophagy .

What methods are recommended for investigating TMEM175 variants associated with Parkinson's disease?

TMEM175 variants have been implicated in Parkinson's disease, particularly affecting protein aggregation processes: (1) CRISPR/Cas9 gene editing to introduce disease-associated variants into cellular or animal models; (2) Patient-derived induced pluripotent stem cells (iPSCs) differentiated into neurons for phenotypic analysis; (3) Alpha-synuclein aggregation assays comparing wild-type and mutant TMEM175 backgrounds; (4) Lysosomal function assessments including pH regulation, enzyme activity, and substrate degradation; (5) Proteomics approaches to identify alterations in the lysosomal protein network associated with TMEM175 variants. When designing such studies, researchers should consider both loss-of-function and altered-function hypotheses, as mutations might impact channel selectivity, conductance properties, or regulatory interactions rather than simply reducing expression .

How can researchers accurately assess the impact of TMEM175 dysfunction on neurodegeneration?

For studying TMEM175's role in neurodegeneration: (1) Long-term neuronal culture systems with TMEM175 knockdown or expression of disease-associated variants; (2) Neuron-specific conditional knockout animal models with behavioral, electrophysiological, and histological assessments; (3) Protein aggregation monitoring using fluorescent reporters or biochemical fractionation techniques; (4) Mitochondrial function analysis, given the interplay between lysosomal and mitochondrial health; (5) Calcium homeostasis measurements, as lysosomal calcium signaling impacts neuronal function. These approaches should track age-dependent and progressive changes that might mimic neurodegenerative disease trajectories, focusing on both acute cellular responses and chronic adaptations to TMEM175 dysfunction .

What are the most effective experimental approaches for targeting TMEM175 therapeutically?

Therapeutic targeting of TMEM175 presents unique challenges requiring specialized approaches: (1) High-throughput screening assays using lysosomal pH sensors to identify compounds that modulate TMEM175 activity; (2) Structure-based drug design targeting specific domains once crystal structures become available; (3) Gene therapy approaches for delivery of functional TMEM175 to compensate for disease-associated variants; (4) Allosteric modulator screening to identify compounds that enhance remaining TMEM175 function in partial loss-of-function scenarios; (5) Indirect targeting of pathways that regulate TMEM175 expression or trafficking to lysosomes. When designing therapeutic strategies, researchers should consider the dual ion selectivity of TMEM175 and aim to restore specific aspects of channel function that are most relevant to disease pathogenesis .

How can researchers resolve issues with non-specific binding in TMEM175 antibody applications?

Non-specific binding with TMEM175 antibodies can be addressed through multiple strategies: (1) Optimize blocking conditions using different blocking agents (BSA, milk, normal serum); (2) Increase washing stringency with higher salt concentrations or mild detergents; (3) Titrate antibody concentrations to find the optimal signal-to-noise ratio; (4) Use validated blocking peptides specific to the antibody's epitope to confirm signal specificity; (5) Pre-absorb antibodies with tissue or cell lysates from species with low homology to reduce cross-reactivity. The use of blocking peptides like BLP-PC175 has been particularly effective in confirming signal specificity in both western blot and immunohistochemistry applications, as demonstrated by the complete suppression of signal when antibodies are pre-incubated with these peptides .

What strategies help overcome challenges in detecting TMEM175 in specific subcellular compartments?

For improved subcellular detection of TMEM175: (1) Use super-resolution microscopy techniques (STED, STORM) to resolve endosomal/lysosomal structures below the diffraction limit; (2) Perform subcellular fractionation to isolate enriched endosomal and lysosomal compartments before western blotting; (3) Employ co-localization studies with established markers (LAMP1, RAB proteins) to confirm appropriate compartment localization; (4) Consider permeabilization conditions carefully—different detergents (saponin, digitonin, Triton X-100) provide varying access to intracellular membranes; (5) Use epitope tags in overexpression systems when antibody sensitivity is limiting, though tag-based detection should be validated against endogenous protein localization. These approaches help overcome the challenges associated with detecting a transmembrane protein in complex intracellular membrane systems .

How should researchers address data inconsistencies when comparing different TMEM175 antibodies?

When facing inconsistent results with different TMEM175 antibodies: (1) Systematically compare epitope locations—antibodies targeting different domains may yield different results based on protein conformation or processing; (2) Validate each antibody individually using knockdown/knockout controls; (3) Consider fixation and sample preparation differences that might affect epitope accessibility; (4) Evaluate potential post-translational modifications that might affect antibody recognition; (5) Consult literature for known splice variants or isoforms that might be differentially detected. A comprehensive validation approach using multiple antibodies in parallel can help establish which signals represent true TMEM175 detection versus artifacts. Remember that antibodies recognizing different epitopes may provide complementary information rather than contradictory data .